This CME-accredited, case-based activity is designed to enhance clinical decision-making through the application of current evidence and best practices in GU oncology. Learners will engage with interactive scenarios that emphasize personalized treatment approaches, safe use of emerging therapies, and effective management of treatment-related toxicities.
Course Accreditations
Course Summary
| Events Starts | Events Ends |
|---|---|
| 1/1/2025 | 12/31/2025 |
Faculty
Umang Swami (MD)
Umang Swami is an Assistant Professor in Department of Oncology at Huntsman Cancer Institute with a focus on genitourinary cancers. He completed his Medical School from Sawai Man Singh Medical College, India. Thereafter he worked as a Visiting Scientist at Montefiore-Einstein Cancer Center, NY and collaborated on phase I studies of novel drugs and regimens for patients with refractory or advanced solid tumors. He did his residency training in Internal Medicine at St. Barnabas Hospital, NY, Hematology-Oncology fellowship from University of Iowa and completed MS in Clinical Investigations from College of Public Health at University of Iowa. He has published more than 70 articles in peer reviewed journals and serves on multiple international guideline panels.
Disclosure
Financial relationships Yes, I have had a financial relationship with an ineligible company within the past 24 months. Financial relationships: Attribution: Self Type of financial relationship: Other Ineligible company: Astellas Topic: consultancy Attribution: Self Type of financial relationship: Other Ineligible company: Exelixis Topic: consultancy Attribution: Self Type of financial relationship: Other Ineligible company: Seattle Genetics Topic: consultancy Attribution: Self Type of financial relationship: Other Ineligible company: Gilead Topic: consultancy Attribution: Self Type of financial relationship: Other Ineligible company: ImVax Topic: consultancy Attribution: Self Type of financial relationship: Other Ineligible company: Sanofi Topic: consultancy Attribution: Self Type of financial relationship: Other Ineligible company: AstraZeneca Topic: consultancy Attribution: Self Type of financial relationship: Other Ineligible company: Adaptimmune Topic: consultancy Attribution: Self Type of financial relationship: Other Ineligible company: Pfizer Topic: consultancy Attribution: Self Type of financial relationship: Other Ineligible company: Janssen Topic: consultancy Attribution: Self Type of financial relationship: Other Ineligible company: Flatiron Health Topic: consultancy
- Medical oncologists
- Radiation oncologists
- Surgical oncologists
- Oncology residents/fellows
- Oncology NPs/PAs
- Oncology pharmacists
- Oncology nurses
Target Audience
- Evaluate current evidence to inform treatment decisions in patients with advanced genitourinary cancers.
- Integrate biomarker testing into clinical practice to guide personalized therapy.
- Recognize and manage adverse effects associated with novel targeted therapies.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to: